Abstract
Increasingly, MCOs ask pharmaceutical companies for evidence of a new product's cost effectiveness before adding it to the formulary. This article examines a research partnership between a pharmaceutical company and 14 MCOs to assess the cost effectiveness of a new medication for osteoarthritis. The research partnership, a study protocol, and research activities are discussed.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / economics
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Cooperative Behavior*
-
Cost-Benefit Analysis
-
Cyclooxygenase Inhibitors / adverse effects
-
Cyclooxygenase Inhibitors / economics
-
Cyclooxygenase Inhibitors / therapeutic use
-
Drug Industry / organization & administration*
-
Formularies as Topic*
-
Humans
-
Managed Care Programs / organization & administration*
-
Meloxicam
-
Osteoarthritis / drug therapy
-
Research / organization & administration
-
Thiazines / adverse effects
-
Thiazines / economics
-
Thiazines / therapeutic use
-
Thiazoles / adverse effects
-
Thiazoles / economics
-
Thiazoles / therapeutic use
-
United States
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cyclooxygenase Inhibitors
-
Thiazines
-
Thiazoles
-
Meloxicam